Oncology
Director & Head – Pediatric Hematology Oncology and Bone Marrow Transplantation18 Years of Experience in Pediatric Hematology Oncology and Bone Marrow Transplantation
HCG Cancer Hospital, K R Road
Bangalore
Dr. Intezar Mehdi is a senior Pediatric Hemato-Oncologist and Bone Marrow Transplant specialist in Bengaluru with 18 years of experience in the diagnosis and treatment of childhood cancers and blood disorders.
He serves as Director and Head of the Department of Pediatric Hematology Oncology and BMT and has extensive experience in treating childhood leukemia, lymphoma, histiocytosis syndromes, central nervous system tumors, bone tumors, Wilms tumor, neuroblastoma, sarcomas and other pediatric solid tumors.
Dr. Intezar Mehdi also specialises in the management of non-malignant blood disorders in children, including thalassemia, sickle cell anemia, autoimmune hemolytic anemia, immune thrombocytopenia, platelet disorders, hemophilia and other bleeding disorders.
He is experienced in both autologous and allogeneic blood and bone marrow transplantation for hematological and oncological malignancies as well as selected benign conditions such as thalassemia and aplastic anemia.
Dr. Intezar Mehdi completed his MBBS and DNB in Paediatrics and subsequently obtained MRCPCH and FRCPCH qualifications from the United Kingdom. He is actively involved in pediatric oncology research, academic teaching, professional societies and scientific publications.
Childhood leukemia treatment is planned according to the leukemia subtype, risk classification, response to therapy and overall health of the child.
ALL is one of the most common childhood blood cancers and requires structured pediatric oncology treatment with careful response assessment and long-term follow-up.
Pediatric AML requires specialised hematology-oncology care and may involve intensive therapy and bone marrow transplantation in selected high-risk or relapsed cases.
Hodgkin lymphoma treatment in children is planned according to disease stage, risk group and treatment response with the aim of achieving disease control while limiting long-term treatment effects.
Pediatric Non-Hodgkin lymphoma treatment depends on lymphoma subtype, stage and risk category and requires specialised pediatric oncology management.
Histiocytosis syndromes in children require specialised assessment and treatment according to the organs involved, disease severity and clinical presentation.
Pediatric central nervous system tumors require multidisciplinary management based on tumor type, location, age and disease extent.
Childhood bone tumors require coordinated oncology care involving systemic treatment and local tumor management according to tumor type and stage.
Wilms tumor is a childhood kidney cancer managed through coordinated pediatric oncology treatment based on stage, pathology and response to therapy.
Neuroblastoma treatment is based on age, tumor biology, stage and risk classification, with intensive therapy considered for selected high-risk cases.
Pediatric sarcomas require multimodal cancer care based on tumor subtype, location, stage and response to systemic treatment.
Autologous transplantation uses the patient's own previously collected blood-forming stem cells to restore bone marrow function after intensive treatment.
Allogeneic transplantation uses healthy blood-forming stem cells from a compatible donor and may be used for selected malignant and non-malignant blood disorders.
Thalassemia management includes long-term hematology care and, for appropriately selected children, consideration of bone marrow transplantation.
Sickle cell anemia requires ongoing hematology care to prevent and manage complications and may involve transplantation in selected patients.
Aplastic anemia is a bone marrow failure disorder that requires specialised hematology assessment, supportive care and, in selected cases, bone marrow transplantation.
Immune thrombocytopenia management is based on platelet count, bleeding symptoms and individual risk and may range from observation to medical treatment.
Hemophilia care focuses on prevention and treatment of bleeding episodes through specialised hematology management and appropriate replacement therapy.
MBBS, DNB (Paediatrics), MRCPCH (UK), FRCPCH (UK)
Childhood Leukemia Treatment, Acute Lymphoblastic Leukemia (ALL) Treatment, Acute Myeloid Leukemia (AML) Treatment, Hodgkin Lymphoma Treatment, Non-Hodgkin Lymphoma Treatment, Histiocytosis Management, CNS Tumor Treatment, Bone Tumor Treatment, Wilms Tumor Treatment, Neuroblastoma Treatment, Pediatric Sarcoma Treatment, Autologous Bone Marrow Transplantation, Allogeneic Bone Marrow Transplantation, Thalassemia Management, Sickle Cell Anemia Management, Aplastic Anemia Management, Autoimmune Hemolytic Anemia Management, ITP Management, Platelet Disorder Management, Hemophilia Management
Genuine patient experiences and treatment feedback.
Quick answers to common questions about Dr. Intezar Mehdi
Yes. HCG specifically lists thalassemia, sickle cell anemia and other benign hematological disorders among Dr. Intezar Mehdi's areas of expertise.
His documented expertise includes CNS tumors, bone tumors, Wilms tumor, neuroblastoma, sarcomas and other childhood solid tumors.
Yes. Dr. Intezar Mehdi is experienced in both autologous and allogeneic blood and bone marrow transplantation for childhood malignancies and selected benign blood disorders.
Yes. Dr. Intezar Mehdi has documented expertise in treating childhood Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia.
Dr. Intezar Mehdi's qualifications include MBBS, DNB in Paediatrics, MRCPCH (UK) and FRCPCH (UK).
Contact us for personalized help or to schedule an appointment.